Zsolt Harsanyi

CIK: 0001380184

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (40.0%)

Derivative conversions

Awards (A)3 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

APVO

Aptevo Therapeutics Inc.

Director

EBS

Emergent BioSolutions Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

APVO
Aptevo Therapeutics Inc.
Aug 6, 2026
Exercise(M)
Direct
400 shares-
EBS
Emergent BioSolutions Inc.
Apr 30, 2026
Award(A)
Direct
25.3K shares-
APVO
Aptevo Therapeutics Inc.
Aug 6, 2025
Award(A)
Restricted Stock Unit
Direct
7.2K shares-
APVO
Aptevo Therapeutics Inc.
Jul 17, 2025
Exercise(M)
Direct
1 shares-
EBS
Emergent BioSolutions Inc.
Apr 30, 2025
Award(A)
Direct
34.4K shares-

		Type	Shares	Price		Ownership
Aug 6, 2026	APVO Aptevo Therapeutics Inc.	Exercise(M)	400	-	$0	Direct
Apr 30, 2026	EBS Emergent BioSolutions Inc.	Award(A)	25,344	-	$0	Direct
Aug 6, 2025	APVO Aptevo Therapeutics Inc.	Award(A) Restricted Stock Unit	7,200	-	-	Direct
Jul 17, 2025	APVO Aptevo Therapeutics Inc.	Exercise(M)	1	-	-	Direct
Apr 30, 2025	EBS Emergent BioSolutions Inc.	Award(A)	34,403	-	-	Direct

1-5 of 5 transactions

About Harsanyi Zsolt

Harsanyi Zsolt (SEC CIK 0001380184) files insider reports with the SEC as Director of Aptevo Therapeutics Inc. (APVO) and Chairman of Emergent BioSolutions Inc. (EBS).

Signal8 holds 5 ownership filings by Harsanyi Zsolt, all Form 4s, filed between May 2, 2025 and Aug 10, 2026. Those filings report 5 transactions, from Apr 30, 2025 to Aug 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Harsanyi Zsolt's filings is in SEATTLE, WA.

Recent filings by Harsanyi Zsolt

Aug 6, 2026: Option exercise of APVO shares (Form 4, code M).
Apr 30, 2026: Grant or award of EBS shares (Form 4, code A).
Aug 6, 2025: Grant or award of APVO derivative securities (Form 4, code A).
Jul 17, 2025: Option exercise of APVO shares (Form 4, code M).
Apr 30, 2025: Grant or award of EBS shares (Form 4, code A).

Other insiders filing for Aptevo Therapeutics Inc. (APVO)

Lamothe Jeffrey G., President and CEO
Taylor Daphne, SVP, CFO
Kwon SoYoung, SVP, GC, BD & Corp Affairs
Huebner Dirk, SVP, CMO
Grant Grady III, Director
White Marvin L, Executive Chair

How to read Form 4 transaction codes